What price ranges were reported for Julie Rubinstein's ADPT share sales?

The reported weighted-average prices and transaction ranges were: October 27, 2026—$26.58 ($26.04 to $27.02, inclusive) and $27.53 ($27.07 to $27.98, inclusive); October 28, 2026—$28.44 ($27.85 to $28.84, inclusive) and $28.90 ($28.88 to $28.92, inclusive); October 29, 2026—$28.27 ($27.92 to $28.73, inclusive).

Adaptive Biotechnologies COO sells 35,643 shares

Q: How many shares did ADPT's president sell?

Julie Rubinstein reported sales totaling 35,643 shares from October 27, 2026 through October 29, 2026. On each of those dates, she also exercised options to acquire 11,881 common shares.

The president and COO's transactions were effected pursuant to a Rule 10b5-1 plan adopted November 18, 2025, and the options were fully vested and exercisable.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

At Adaptive Biotechnologies Corp, President and COO Julie Rubinstein exercised 11,881 stock options at $12.14 per share on each of October 27, 2026, October 28, 2026 and October 29, 2026. Sales comprised 3,000 shares at a weighted average price of $26.58 and 8,881 at $27.53 on October 27, 2026; 11,681 at $28.44 and 200 at $28.90 on October 28, 2026; and 11,881 at $28.27 on October 29, 2026. The transactions were effected pursuant to a Rule 10b5-1 plan adopted November 18, 2025; the options were fully vested and exercisable.

Insider Trade Summary 10b5-1

Exercise and Sale: 35,643 shares ($565K approx. pre-tax spread)

Exercise and Sale 11 txns

Insider RUBINSTEIN JULIE

Role President and COO

Sold 35,643 shs ($998K)

Approx. gross sale proceeds $998K

Approx. exercise cost $433K

Approx. pre-tax spread $565K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) ^{F1, F7}	11,881	$0.00	$0.00
Exercise	Common Stock ^F1	11,881	$12.14	$144K
Sale	Common Stock ^{F1, F6}	11,881	$28.27	$336K
Exercise	Stock Option (right to buy) ^{F1, F7}	11,881	$0.00	$0.00
Exercise	Common Stock ^F1	11,881	$12.14	$144K
Sale	Common Stock ^{F1, F4}	11,681	$28.44	$332K
Sale	Common Stock ^{F1, F5}	200	$28.90	$6K
Exercise	Stock Option (right to buy) ^{F1, F7}	11,881	$0.00	$0.00
Exercise	Common Stock ^F1	11,881	$12.14	$144K
Sale	Common Stock ^{F1, F2}	3,000	$26.58	$80K
Sale	Common Stock ^{F1, F3}	8,881	$27.53	$244K

Holdings After Transaction: Stock Option (right to buy) — 130,276 contracts (Direct); Common Stock — 377,802 shares (Direct)

Footnotes (7)

F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.04 to $27.02, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.07 to $27.98, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.85 to $28.84, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.88 to $28.92, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F6. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.92 to $28.73, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F7. The option is fully vested and exercisable.

Key Figures

Common shares acquired through option exercises: 11,881 shares Option exercise price: $12.14 per share Shares sold: 3,000 shares at a weighted average price of $26.58 per share +4 more

7 metrics

Common shares acquired through option exercises 11,881 shares On each of October 27, 2026, October 28, 2026 and October 29, 2026

Option exercise price $12.14 per share For the options exercised on October 27, 2026, October 28, 2026 and October 29, 2026

Shares sold 3,000 shares at a weighted average price of $26.58 per share October 27, 2026

Shares sold 8,881 shares at a weighted average price of $27.53 per share October 27, 2026

Shares sold 11,681 shares at a weighted average price of $28.44 per share October 28, 2026

Shares sold 200 shares at a weighted average price of $28.90 per share October 28, 2026

Shares sold 11,881 shares at a weighted average price of $28.27 per share October 29, 2026

Key Terms

Rule 10b5-1 trading plan, weighted average price, fully vested and exercisable, Stock Option (right to buy)

4 terms

Rule 10b5-1 trading plan financial

"effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported for this transaction is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

fully vested and exercisable technical

"The option is fully vested and exercisable"

Stock Option (right to buy) technical

"Stock Option (right to buy)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did ADPT's president sell?

Julie Rubinstein reported sales totaling 35,643 shares from October 27, 2026 through October 29, 2026. On each of those dates, she also exercised options to acquire 11,881 common shares.

Were Julie Rubinstein's ADPT transactions made under a trading plan?

Julie Rubinstein's transactions were effected pursuant to a Rule 10b5-1 trading plan adopted November 18, 2025. The exercised options were fully vested and exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/29/2026 - 07:53 PM EDT Accepted by SEC EDGAR 10/29/2026 - 07:52 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RUBINSTEIN JULIE

(Last)

(First)

(Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE

WASHINGTON

98109

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and COO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/27/2026		M⁽¹⁾		11,881	A	$12.14	389,683	D
Common Stock	10/27/2026		S⁽¹⁾		3,000	D	$26.58⁽²⁾	386,683	D
Common Stock	10/27/2026		S⁽¹⁾		8,881	D	$27.53⁽³⁾	377,802	D
Common Stock	10/28/2026		M⁽¹⁾		11,881	A	$12.14	389,683	D
Common Stock	10/28/2026		S⁽¹⁾		11,681	D	$28.44⁽⁴⁾	378,002	D
Common Stock	10/28/2026		S⁽¹⁾		200	D	$28.9⁽⁵⁾	377,802	D
Common Stock	10/29/2026		M⁽¹⁾		11,881	A	$12.14	389,683	D
Common Stock	10/29/2026		S⁽¹⁾		11,881	D	$28.27⁽⁶⁾	377,802	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$12.14	10/27/2026		M⁽¹⁾			11,881	⁽⁷⁾	03/04/2032	Common Stock	11,881	$0	154,038	D
Stock Option (right to buy)	$12.14	10/28/2026		M⁽¹⁾			11,881	⁽⁷⁾	03/04/2032	Common Stock	11,881	$0	142,157	D
Stock Option (right to buy)	$12.14	10/29/2026		M⁽¹⁾			11,881	⁽⁷⁾	03/04/2032	Common Stock	11,881	$0	130,276	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.04 to $27.02, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

3. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.07 to $27.98, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.85 to $28.84, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

5. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.88 to $28.92, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

6. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.92 to $28.73, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

7. The option is fully vested and exercisable.

	/s/ Julie Rubinstein by Kyle Piskel, Attorney-in-Fact	10/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR